3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
9
NIH
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Head & Neck
2
Gastrointestinal
2
Dermatologic
2
Conditions
Neoplasms
38
Melanoma
36
Carcinoma, Non-Small-Cell Lung
16
Colorectal Neoplasms
10
Pancreatic Neoplasms
5
Neoplasm Metastasis
4
Glioma
4
Triple Negative Breast Neoplasms
3
Skin Neoplasms
3
Multiple Myeloma
3
Lung Neoplasms
3
Biliary Tract Neoplasms
3
Thyroid Neoplasms
2
Rectal Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Oligodendroglioma
2
Neurofibroma, Plexiform
2
Neurocytoma
2
Neuroblastoma
2
Leukemia, Myeloid, Acute
2
Histiocytosis, Langerhans-Cell
2
Glioblastoma
2
Ganglioneuroma
2
Ganglioglioma
2
Colonic Neoplasms
2
Brain Neoplasms
2
Astrocytoma
2
Advanced Solid Tumors
2
Adenocarcinoma of Lung
2
Uveal Melanoma
1
Interventions
lenvatinib
9
vandetanib
5
pembrolizumab
4
Sorafenib
4
selpercatinib
3
Thyrotropin Alfa
3
trametinib
2
fosbretabulin
2
combretastatin
2
cabozantinib
2
belinostat
2
Paclitaxel
2
Gemcitabine
2
Fluorouracil
2
Cetuximab
2
Carboplatin
2
Axitinib
2
130-nm albumin-bound paclitaxel
2
ulixertinib
1
trastuzumab deruxtecan
1
tipifarnib
1
surufatinib
1
repotrectinib
1
pralsetinib
1
naporafenib
1
motesanib diphosphate
1
methyl N-acetylsibirosaminide
1
larotrectinib
1
irofulven
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Thyroid Neoplasms
×
trametinib
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled
NCT05275374
2025-04-10
ENHANCE
Xynomic Pharmaceuticals, Inc.
Phase 1/2
Not yet recruiting
221 enrolled